Byongen Therapeutics to Showcase Breakthrough AAV Capsid Evolution Data at the ASGCT 28th Annual Meeting

NEW ORLEANS, LA – Byongen Therapeutics, a biotechnology company specializing in next-generation viral vector engineering, today announced that it will present the latest breakthroughs from its proprietary DynEvoLib® capsid evolution platform at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT 2025).

The presentation will spotlight pioneering results from NHP (Non-Human Primate) screening, demonstrating the successful identification of tissue-tropic AAV variants with superior transduction efficiency and target specificity across systemic and local delivery routes.

📌Poster Presentation Details

Abstract Title: An Improved Approach Enables Efficient and Cost-effective Directed Evolution of AAV Capsids in Non-human Primates via Different Delivery Routes

Poster Number: #1397

Date & Time: Wednesday, May 14, 2025 | 5:30 PM – 7:00 PM (CDT)

Session: Wednesday Poster Reception

Location: Poster Hall, Hall I2

Byongen’s DynEvoLib^® platform integrates high-throughput NHP screening with diverse administration routes (IV, IT, and local injection) to streamline the discovery of clinical-enabling AAV vectors.

⭐️Key Presentation Highlights

BY087: Next-Generation Myotropic & Cardiotropic Variant

Demonstrated a 21-fold increase in skeletal muscle and a 13-fold increase in cardiac muscle transduction compared to AAV9 in NHPs. Exhibits robust cross-species tropism (NHP, rat, and mouse), ideal for treating Duchenne muscular dystrophy (DMD) and other systemic muscular disorders.

BY213: Potent CNS-Tropic Variant (Systemic Delivery)

Achieved a 30-fold enhancement in CNS transduction via intravenous (IV) administration compared to AAV9, offering a non-invasive solution for widespread neurodegenerative diseases.

BY368: High-Efficiency CNS Variant (Intrathecal Delivery)

Delivered a massive 98-fold increase in CNS transduction via intrathecal (IT) injection compared to AAV9, unlocking new possibilities for targeting refractory brain disorders.

"Our findings underscore the transformative potential of the DynEvoLib^® platform in bridging the gap between library discovery and large-animal validation," said Gang Wang, Ph.D., Founder and CEO of Byongen Therapeutics. "By delivering unprecedented potency and tissue specificity in NHPs, these novel capsids provide a robust foundation for the next generation of life-changing gene therapies."

Byongen Therapeutics invites potential biopharma partners, researchers, and investors to visit our poster session to discuss collaborative opportunities for advancing these candidates toward clinical development.

About Byongen Therapeutics

Byongen Therapeutics is a biotechnology company focused on original innovation in AAV delivery technologies. The company aims to address core clinical delivery bottlenecks through capsid engineering. By leveraging its proprietary DynEvoLib^® platform, Byongen integrates AI, rational design, and high-throughput directed evolution to develop next-generation AAV capsids. Byongen’s R&D focus targets the development of specialized capsids for neuromuscular and central nervous system (CNS) diseases.